Beacon's AI platform for brain data enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through novel machine learning algorithms, enormous datasets, and advances in software engineering, we are changing the way patients are treated for disorders of the brain.
Location: United States
Employees: 11-50
Total raised: $113M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 26.09.2021 | Synetro Gr... | synetro.co... |
| - | Indicator ... | indicatorv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.11.2025 | Series B | $86M | Takeda Ven... |
| 09.11.2021 | Series A | $27M | - |
Mentions in press and media 16
| Date | Title | Description |
| 06.04.2026 | Beacon Biosignals Raises $11M; Brings Series B Financing to Over $97M | Beacon Biosignals, a Boston, MA-based company leveraging brain data to advance human health, raised an $11m extension to its Series B financing, bringing the funding round to $97m the cumulative funding to over $132m. The upsized round incl... |
| 18.11.2025 | Beacon Biosignals Secures $86M to Revolutionize Brain Disorder Treatment | Beacon Biosignals landed $86M in Series B funding. They plan to use it to improve diagnostics and treatment using AI. Their neurotechnology targets brain disorders. The funding helps them expand and accelerate discovery. This positions them... |
| 17.11.2025 | Beacon Biosignals aglow with $86M haul for neurodiagnostic data | Beacon Biosignals, known for its sleep monitoring system, hauled in $86 million as part of an oversubscribed series B funding round that will be used to develop a new neurodiagnostic data set. The fundraising is part of the company’s effort... |
| 16.11.2025 | Beacon Biosignals: $86 Million Series B Raised To Advance AI-Driven Neurodiagnostics And Precision Neuroscience | Beacon Biosignals has raised an oversubscribed $86 million Series B to accelerate the clinical adoption of AI-powered biomarkers for neurological and psychiatric disease, expand its precision medicine data platform, and scale its neurodiagn... |
| 13.11.2025 | Beacon Biosignals Raises $86M in Series B Funding | Beacon Biosignals, a Boston, MA-based neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, raised $86m in Series B funding. Backers included Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, ... |
| 24.04.2024 | DATAcc by DiMe Launches Core Measures for Sleep | Core sleep measures and resources will help transform sleep research and care to advance the treatment of multiple disease areas BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) b... |
| 27.03.2024 | BEACON BIOSIGNALS EXPANDS SLEEP ANALYSIS CAPABILITIES WITH FDA CLEARANCE OF SLEEPSTAGEML | MILESTONE BROADENS THE COMPANY'S ANALYSIS PLATFORM, EXTENDING ITS APPLICATION FROM AT-HOME SLEEP MONITORING TO ALSO INCLUDE COMPREHENSIVE COVERAGE OF TRADITIONAL IN-LAB POLYSOMNOGRAPHY. BOSTON, March 27, 2024 /PRNewswire/ -- Beacon Biosigna... |
| 13.07.2023 | Beacon Biosignals Acquires Dreem | Beacon Biosignals, a Boston, MA-based computational neurodiagnostics and electroencephalogram (EEG) analytics company, acquired Dreem, a Paris, France-based company which specializes in at-home sleep monitoring. The amount of the deals as n... |
| 14.11.2021 | Neurotech startup Beacon Biosignals scores $27M to bring AI to EEG analysis | Electroencephalography is a decades-old technique for capturing brain activity, data that are used to evaluate brain disorders. Beacon Biosignals is applying artificial intelligence to these tests, and the neurotechnology startup has found ... |
| 09.11.2021 | Beacon Biosignals Raises $27M in Series A | Beacon Biosignals, a Boston MA-based neurotechnology company, raised $27M in Series A funding. The round, which brought Beacon Biosignals’ total funding to date to $30m, was led by General Catalyst and with participation from Casdin Capital... |
Show more